Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism EGFR exon 20 inhibitors(EGFR exon 20 Mutation inhibitors), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR ex20ins mutation in non-small cell lung cancer | Phase 1 | CN | ![]() | - |
HER2 ex20ins mutation in non-small cell lung cancer | IND Approval | CN | ![]() | 28 Jun 2023 |